 |
1,003 |
| |
The total number of daily visitors to Glycosmedia
passes 1,000. This is a remarkable milestone because there has
been no formal promotion of the news service. (Jim Young, Editor) |
| |
|
|
Appropriate
advancement of type 2 diabetes therapy |
| |
Recent guidelines recommend rapid advancement
of antiglycemic therapy, with early initiation of insulin as a
practical and effective option, but they offer little guidance
for primary care physicians with respect to the practical implementation
and inclusion of either basal or rapid-acting analogs into treatment
regimens.These guidelines also do not adequately address the therapeutic
role of some newer agents (eg, the incretin group). An editorial
workgroup meeting consisting of a multidisciplinary panel of diabetes
thought leaders recently convened to provide additional insight
on these issues. Their recommendations and viewpoints are reported
in this supplement (Current Clinical Practice) |
| |
|
|
Generex
Announces Enrollment of Initial Subjects in Metformin Gum Trial |
| |
The protocol for the study is an open-label,
two-treatment, two-period, randomized, crossover study comparing
MetControl™ and immediate release Metformin tablets in healthy volunteers (Generex Biotechnology
Corporation, USA) |
| |
|
|
Joslin
receives $3 Million to study obesity |
| |
Joslin Diabetes Center has received a three-year,
$3 million grant from the Eli Lilly and Company Foundation to help
fund studies that will investigate the underlying causes of obesity
and insulin resistance (Renal Business Today) |
| |
|
|
Beta-cell
function improved with R-1583, a novel long-acting GLP-1 analogue |
| |
Researchers at Roche have reported phase II
results from an 8-week, double-blind, placebo-controlled study
evaluating taspoglutide (R-1583), a glucagon-like peptide-1 (GLP-1)
receptor agonist, in type 2 diabetes patients inadequately controlled
with metformin (American Diabetes Association) |
| |
|
|
Glutamic
acid decarboxylase may help to preserve residual insulin secretion |
| |
Treatment with alum-formulated glutamic acid
decarboxylase contributed to the preservation of residual insulin
secretion in patients with recent-onset type 1 diabetes, but did
not change the insulin requirement in a recent study (Endocrine
Today) |
| |
|
|
Novo
Nordisk Assigns Inhaled Insulin Patent Portfolio to Aradigm |
| |
Aradigm Corporation, a specialty pharmaceutical
company, announced that Novo Nordisk transferred to Aradigm, at
no charge, a portfolio of inhaled insulin related patents pursuant
to a license agreement between Aradigm and Novo that was terminated
in May 2008 (PharmaLive) |
| |
|
|
Sponsorship of Glycosmedia |
| |
To offset the costs of running Glycosmedia the
editors will be starting a search for sponsorship in the near future.
Full details can be obtained from (Jim Young, Editor) |
| |
|
